- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:15 | Annexin Pharmaceuticals AB: Annexin's rights issue 98 percent subscribed | 80 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen | |
| 23.06. | Annexin Pharmaceuticals AB: Annexin updates on continuous promising data from the NEXUS study - demonstrating improvement of retinal perfusion in both DR and RVO | 160 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB announces an update on the NEXUS study key preliminary clinical findings. To date, treatment with the drug candidate ANXV has not been associated with limiting safety or tolerability... ► Artikel lesen | |
| 15.06. | Annexin Pharmaceuticals AB: The subscription period in Annexin Pharmaceuticals' rights issue begins today | 148 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen | |
| 12.06. | Listing of subscription rights and paid subscription shares of Annexin Pharmaceuticals AB | 224 | GlobeNewswire | With effect from June 15, 2026, the subscription rights in Annexin Pharmaceuticals AB will be traded on First North Growth Market. Trading will continue up until and including June 29, 2026.
... ► Artikel lesen | |
| ANNEXIN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 10.06. | Annexin Pharmaceuticals AB: Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue | 149 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen | |
| 09.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.06.2026 | 531 | Xetra Newsboard | Das Instrument G85 CA35958L1013 FUERTE METALS CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 09.06.2026 und ex Kapitalmassnahme am 10.06.2026 The instrument G85 CA35958L1013 FUERTE METALS CORP.... ► Artikel lesen | |
| 03.06. | Annexin Pharmaceuticals AB: Annexin resolves a rights issue of approximately SEK 20 million, secured to approximately 60 percent, with an overallotment option of up to approximately SEK 5 million | 152 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen | |
| 21.05. | Annexin Pharmaceuticals AB: Annexin investigates a three-day ANXV treatment regimen in patients with RVO | 174 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces a shortening of the ANXV treatment regimen from five to three days at the same dose level. A three-day treatment is expected to strengthen the commercial value... ► Artikel lesen | |
| 11.05. | Annexin Pharmaceuticals AB: Annexin receives clinical trial approval in Germany, widening patient recruitment in the NEXUS study | 200 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces that the company has received an approval for a clinical trial with the drug candidate ANXV by the German Medicines Agency Bundesinstitut für Arzneimittel... ► Artikel lesen | |
| 22.04. | Annexin Pharmaceuticals AB: Annexin accelerates patient recruitment - five patients treated | 202 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces an update on patient recruitment in the ongoing Phase 2a/Proof of Concept study NEXUS, investigating the drug candidate ANXV in retinal vein occlusion (RVO)... ► Artikel lesen | |
| 13.04. | Annexin Pharmaceuticals AB: Annexin secures financing through bridge loan facility and plans a rights issue of approximately SEK 20 million during the summer of 2026 | 203 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB (publ) today announces that the company has secured bridge financing of approximately SEK 4 million and intends to carry out a rights issue of approximately SEK 20 million... ► Artikel lesen | |
| 04.02. | Annexin Pharmaceuticals AB: Favourable findings in Annexin's ongoing Phase 2a study in Diabetic Retinopathy and Retinal Vein Occlusion | 540 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces favourable findings in the company's ongoing Proof of Concept Phase 2a study with the drug candidate ANXV in Diabetic Retinopathy (DR) and Retinal Vein Occlusion... ► Artikel lesen | |
| 05.12.25 | Annexin Pharmaceuticals AB: First patients treated in Annexin's Phase 2a study in diabetic retinopathy and RVO | 264 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces that the first two patients have been dosed in the company's Proof of Concept Phase 2a study with the drug candidate ANXV in diabetic retinopathy (DR) and... ► Artikel lesen | |
| 16.09.25 | Annexin Pharmaceuticals AB: Annexin appoints world-leading ophthalmology experts to Medical Advisory Board | 246 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB has appointed a Medical Advisory Board in Ophthalmology. The independent clinical experts in the Board will act as key advisors to the Annexin team advancing the clinical... ► Artikel lesen | |
| 07.08.25 | Annexin Pharmaceuticals AB: Annexin receives approval for Phase 2a study in diabetic retinopathy and RVO | 337 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to start a clinical Proof of Concept phase 2a study with the drug candidate ANXV... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 132,92 | +0,01 % | AbbVie setzt mit Apogee-Übernahme neuen Akzent im Wettlauf um Blockbuster-Biologika | AbbVie stärkt mit der geplanten Übernahme von Apogee Therapeutics seine Position im Markt für Immunologie-Biologika und vertieft damit eine ohnehin schon dominante Wettbewerbsstellung. Der Deal zielt... ► Artikel lesen | |
| VERA THERAPEUTICS | 41,200 | 0,00 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| IMMUNOVANT | 38,790 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,440 | +0,13 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| RECURSION PHARMACEUTICALS | 3,815 | +0,39 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| TANGO THERAPEUTICS | 29,460 | 0,00 % | TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts | ||
| VOR BIOPHARMA | 20,600 | +0,05 % | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| OLEMA PHARMACEUTICALS | 12,640 | 0,00 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ALUMIS | 26,510 | +0,04 % | ALUMIS INC. - 8-K, Current Report | ||
| NURIX THERAPEUTICS | 23,970 | 0,00 % | Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade | ||
| PRAXIS PRECISION MEDICINES | 318,37 | -0,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| ERASCA | 18,470 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| IMMUNOME | 23,620 | +0,04 % | TD Cowen bestätigt Kaufempfehlung für Argenx und verweist auf IMNM-Potenzial | ||
| DYNE THERAPEUTICS | 23,110 | +0,17 % | Dyne Therapeutics stock initiated at buy by TD Cowen on platform | ||
| ADMA BIOLOGICS | 8,950 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen |
Das Unternehmen ANNEXIN PHARMACEUTICALS AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,130 (+12,62 %) liegt der Kurs bei 1,160 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ANNEXIN PHARMACEUTICALS AB finden Sie auf Wallstreet Online.